Cargando…

Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer

Detalles Bibliográficos
Autores principales:	Davey, Matthew G, Kerin, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841871/ https://www.ncbi.nlm.nih.gov/pubmed/36654912 http://dx.doi.org/10.1177/11782234221145409

Ejemplares similares

Evidence should inform more than prescribing decisions
por: Cowdell, Fiona
Publicado: (2022)

Should oral gavage be abandoned in toxicity testing of endocrine disruptors?
por: Vandenberg, Laura N, et al.
Publicado: (2014)

Should We Prescribe More Protein to Critically Ill Patients?
por: Heyland, Daren K., et al.
Publicado: (2018)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers
por: Li, Qing-xia, et al.
Publicado: (2019)

Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
por: Munzone, Elisabetta, et al.
Publicado: (2018)

Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review
por: Fernandes, Leonor, et al.
Publicado: (2020)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
por: Halim, Freda, et al.
Publicado: (2022)

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer
por: Wu, Minhua, et al.
Publicado: (2021)

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer
por: Leary, Alexandra F, et al.
Publicado: (2007)

Integration of endocrine therapy with targeted agents
por: Johnston, Stephen RD
Publicado: (2008)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact
por: Metovic, Jasna, et al.
Publicado: (2022)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Antimicrobial Agents are Societal Drugs: How Should This Influence Prescribing?
por: Sarkar, Paul, et al.
Publicado: (2012)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer
por: Richard, Vinitha, et al.
Publicado: (2022)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
por: Nahleh, Zeina A, et al.
Publicado: (2020)

Should a Multigene Signature be Used in all Luminal Early Breast Cancers
por: Hajjaji, Nawale, et al.
Publicado: (2019)

Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer
por: Thang, Nguyen Xuan, et al.
Publicado: (2022)

Urban–Rural Variations in Quality-of-Life in Breast Cancer Survivors Prescribed Endocrine Therapy
por: Cahir, Caitriona, et al.
Publicado: (2017)

Oncology providers’ perspectives on endocrine therapy prescribing and management
por: Wheeler, Stephanie B, et al.
Publicado: (2016)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis
por: Davey, M.G., et al.
Publicado: (2021)

Oral Anticoagulant Therapy: When What Should Not Be Is and What Should Be Is Not
por: Reiffel, James A.
Publicado: (2019)

A high-risk luminal A dominant breast cancer subtype with increased mobility
por: Guo, Liping, et al.
Publicado: (2019)

Erythromycin for prokinesis: imprudent prescribing?
por: Dall'Antonia, Martino, et al.
Publicado: (2006)

Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
por: Liu, Qiuyue, et al.
Publicado: (2022)

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
por: Martí, Covadonga, et al.
Publicado: (2020)

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
por: Wang, Yunmei, et al.
Publicado: (2020)

Should I stay or should I go?
por: Busch, Karl Emanuel, et al.
Publicado: (2012)

Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer
por: McDermott, Ailbhe M., et al.
Publicado: (2014)

Should all adjuvant breast cancer patients receive a bisphosphonate?
por: Cameron, David A
Publicado: (2003)

Breast cancer research: where we are and where we should go
por: Liu, Edison T
Publicado: (2000)

Quality of care should be a core consideration in health systems recovery from COVID-19
por: Neilson, Matthew, et al.
Publicado: (2021)

Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators
por: Richard, Vinitha, et al.
Publicado: (2023)

Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?
por: White, Harvey D
Publicado: (2000)

Molecular profiling in contemporary breast cancer management
por: Davey, Matthew G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lhmgjhnhe7dfo4kmvgq7ou434t